News
VNDA
4.380
-3.31%
-0.150
Weekly Report: what happened at VNDA last week (0106-0110)?
Weekly Report · 2d ago
Vanda asserts FDA review of tradipitant was flawed
Seeking Alpha · 6d ago
Vanda Pharmaceuticals issues letter to FDA on faulty gastroparesis NDA review
TipRanks · 6d ago
Vanda Pharmaceuticals Pens Letter To FDA Commissioner Regarding Approval For Tradipitant For Treatment Of Patients With Gastroparesis
Benzinga · 6d ago
VANDA'S LETTER TO FDA COMMISSIONER HIGHLIGHTS FAULTY GASTROPARESIS NDA REVIEW
Reuters · 6d ago
VANDA PHARMACEUTICALS: ISSUED LETTER TO FDA REGARDING SEPT. 18, 2024 CRL IN REFERENCE TO CO'S NDA FOR TRADIPITANT FOR TREATMENT OF GASTROPARESIS
Reuters · 6d ago
RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use
NASDAQ · 01/07 15:14
Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?
NASDAQ · 01/06 16:54
Weekly Report: what happened at VNDA last week (1230-0103)?
Weekly Report · 01/06 10:27
KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates
Barchart · 01/06 09:30
Weekly Report: what happened at VNDA last week (1223-1227)?
Weekly Report · 12/30/2024 10:23
Undercovered Dozen: OppFi, PowerFleet, Eletrobras, American Battery +
Seeking Alpha · 12/28/2024 18:00
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
Barchart · 12/24/2024 07:54
Vanda Pharmaceuticals Price Target Maintained With a $18.00/Share by HC Wainwright & Co.
Dow Jones · 12/23/2024 12:01
HC Wainwright & Co. Reiterates Buy on Vanda Pharma, Maintains $18 Price Target
Benzinga · 12/23/2024 11:51
Vanda Pharmaceuticals: Promising Pipeline Developments and Market Potential Drive Buy Rating
TipRanks · 12/23/2024 11:25
Weekly Report: what happened at VNDA last week (1216-1220)?
Weekly Report · 12/23/2024 10:27
Vanda Pharmaceuticals: Net-Net Status Presents A Trading Opportunity
Seeking Alpha · 12/20/2024 18:26
Vanda Pharma's VGT-1849A Gets Orphan Drug Designation From FDA
NASDAQ · 12/20/2024 15:26
Vanda Pharmaceuticals Gets FDA Orphan-Drug Designation for Cancer Treatment
Dow Jones · 12/20/2024 14:37
More
Webull provides a variety of real-time VNDA stock news. You can receive the latest news about Vanda Pharma through multiple platforms. This information may help you make smarter investment decisions.
About VNDA
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).